We aimed to evaluate NKA and methylation of the HOXA9 promoter region as prognostic biomarkers in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Here, HOXA9 is linked to non-small cell lung carcinoma.